Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis

BACKGROUND: Kidney benefits have been demonstrated for both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) compared with placebo in patients with type 2 diabetes. This study aimed to compare the impacts of SGLT2i and GLP1RA on the trend of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, David Tak Wai, Au, Ivan Chi Ho, Tang, Eric Ho Man, Cheung, Ching Lung, Lee, Chi Ho, Woo, Yu Cho, Wu, Tingting, Tan, Kathryn Choon Beng, Wong, Carlos King Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241106/
https://www.ncbi.nlm.nih.gov/pubmed/35784442
http://dx.doi.org/10.1016/j.eclinm.2022.101510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241106/
https://www.ncbi.nlm.nih.gov/pubmed/35784442
http://dx.doi.org/10.1016/j.eclinm.2022.101510

Ejemplares similares